Natera Inc. (NASDAQ: NTRA) announced it will present 35 studies at the 2026 American Society of Clinical Oncology Annual Meeting, scheduled for May 29 to June 2 in Chicago.

The presentations will focus on molecular residual disease testing and the company's Signatera technology. Three of the presentations will be oral presentations at the conference.

The studies include analysis from the GALAXY study in colorectal cancer, which examined the use of Signatera testing in adjuvant treatment decisions. One analysis found that patients who initially tested negative but later converted to positive derived benefit from adjuvant chemotherapy with a hazard ratio of 0.3. Another analysis indicated that extending adjuvant chemotherapy beyond three months provided no additional benefit for patients with sustained negative results.

Natera will present a meta-analysis of Signatera across 18 published studies covering more than 3,000 patients and 15 tumor types. The analysis showed that positive Signatera results were associated with increased risk of recurrence or disease progression. In the adjuvant setting, positive results were associated with a hazard ratio of 8.15 for recurrence or death, while in surveillance settings the hazard ratio was 18.30.

Additional studies will examine the company's phased variant technology, which can detect circulating tumor DNA levels below 1 part per 10 million. One study in early-stage non-small cell lung cancer showed that 100% of patients who cleared circulating tumor DNA during or after adjuvant therapy did not experience recurrence.

The company will also introduce its Annotation platform, a digital tool that integrates clinical, treatment and genomic data to provide longitudinal patient information alongside Signatera results.

The information is based on a company press release statement.